EGFR tyrosine kinase inhibitors treatment was the main strategy for patients diagnosed with lung cancer harbouring EGFR mutations, however, acquired drug resistance limited the treatment efficiency.7, 8, 9. The gene discussed is EGFR; the disease is lung cancer.